Morphologic Correlations with Homologous Recombination Deficiency in BRCA1/2-Mutated and Non-BRCA-Mutated High-Grade Serous Carcinomas

被引：0
|
作者：
Chapagain, Udita [1 ]
Sun, Lulu [2 ]
机构：
[1] Washington Univ St Louis, St Louis, MO USA
[2] Washington Univ, Sch Med, St Louis, MO USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
895
引用
收藏
页码：S1121 / S1122
页数：2
相关论文
共 50 条
  • [11] Morphological feature discrepancies in wild-type vs. BRCA1/BRCA2 mutated high-grade serous ovarian cancer
    Lee, JaeHeon
    Kim, Hyunil
    Lee, Yongeun
    Choi, Yoon-La
    Jung, Kyungsoo
    Kwak, Tae-Yeong
    Kim, Sun Woo
    Chang, Hyeyoon
    CANCER RESEARCH, 2024, 84 (06)
  • [12] Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
    Launonen, I-M
    Lyytikainen, N.
    Casado, J.
    Anttila, E. A.
    Szabo, A.
    Haltia, U-M
    Jacobson, C. A.
    Lin, J. R.
    Maliga, Z.
    Howitt, B. E.
    Strickland, K. C.
    Santagata, S.
    Elias, K.
    D'Andrea, A. D.
    Konstantinopoulos, P. A.
    Sorger, P. K.
    Farkkila, A.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [13] Role of BRCA1 promotor methylation in homologous recombination deficiency (HRD) in high-grade ovarian cancer
    Fiegl, H.
    Reimer, D.
    Schnaiter, S.
    Leitner, K.
    Wimmer, K.
    Schamschula, E.
    Steger, K.
    Marth, C.
    Zeimet, A. G.
    ANNALS OF ONCOLOGY, 2023, 34 : S527 - S527
  • [14] Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
    I.-M. Launonen
    N. Lyytikäinen
    J. Casado
    E. A. Anttila
    A. Szabó
    U.-M. Haltia
    C. A. Jacobson
    J. R. Lin
    Z. Maliga
    B. E. Howitt
    K. C. Strickland
    S. Santagata
    K. Elias
    A. D. D’Andrea
    P. A. Konstantinopoulos
    P. K. Sorger
    A. Färkkilä
    Nature Communications, 13
  • [15] A Clinicopathologic and Molecular Study of BRCA1/2-mutated Pancreatic Ductal Adenocarcinoma
    Li, Hongjie
    Gibson, Joanna
    Jain, Dhanpat
    Finberg, Karin
    Walther, Zenta
    Zhong, Minghao
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1050 - 1051
  • [16] Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma
    Dai, Ying
    Sun, Chengdu
    Feng, Yi
    Jia, Qingzhu
    Zhu, Bo
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018, 22 (08) : 3979 - 3986
  • [17] A Clinicopathologic and Molecular Study of BRCA1/2-mutated Pancreatic Ductal Adenocarcinoma
    Li, Hongjie
    Gibson, Joanna
    Jain, Dhanpat
    Finberg, Karin
    Walther, Zenta
    Zhong, Minghao
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1050 - 1051
  • [18] BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas
    Garg, Karuna
    Levine, Douglas A.
    Olvera, Narciso
    Dao, Fanny
    Bisogna, Maria
    Secord, Angeles Alvarez
    Berchuck, Andrew
    Cerami, Ethan
    Schultz, Nikolaus
    Soslow, Robert A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2013, 37 (01) : 138 - 146
  • [19] Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers.
    Strickland, Kyle
    Howitt, Brooke E.
    Rodig, Scott J.
    Ritterhouse, Lauren
    D'Andrea, Alan D.
    Matulonis, Ursula
    Konstantinopoulos, Panagiotis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [20] Comparative study between patients with mutated BRCA1 2 breast and or ovarian cancer and non-mutated BRCA1 2
    Habak, N.
    Abdellah, M. Ait
    Chikouche, A.
    Griene, L.
    CLINICA CHIMICA ACTA, 2024, 558
12345